Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | SUCNR1 | Q9BXA5 | 14/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.46 |
| ▸ | OXGR1 | Q96P68 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12895009 | 0.87 | PDE10A (0.49) | SUCNR1PDE10AOXGR1TDP1ALDH1A1 | |
| SCHEMBL20517681 | 0.85 | SUCNR1 (0.49) | SUCNR1PDE10AOXGR1 | |
| SCHEMBL9528545 | 0.83 | PDE10A (0.58) | KCNH2PDE10ATDP1L3MBTL1ALDH1A1 | |
| SCHEMBL30930276 | 0.83 | SUCNR1 (0.50) | SUCNR1PDE10AOXGR1 | |
| SCHEMBL6899530 | 0.83 | SUCNR1 (0.47) | SUCNR1PDE10AOXGR1ALDH1A1 | |
| SCHEMBL276117 | 0.83 | SUCNR1 (0.50) | SUCNR1PDE10AOXGR1ALDH1A1 | |
| SCHEMBL10480813 | 0.82 | PDE10A (0.57) | KCNH2PDE10ATDP1L3MBTL1 | |
| SCHEMBL31026567 | 0.82 | PDE10A (0.57) | KCNH2PDE10ATDP1L3MBTL1 | |
| SCHEMBL20481012 | 0.82 | SUCNR1 (0.47) | SUCNR1PDE10AOXGR1ALDH1A1 | |
| SCHEMBL28813000 | 0.82 | PDE10A (0.57) | KCNH2PDE10ATDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115160567-B | Polyimide containing carbon chain naphthyridine ketone structure and preparation method thereof | 大连理工大学 | 2024-04-26 | — | — | CN | disclosed |
| CN-107949562-A | The positive allosteric modulators of muscarinic M2 acceptors | 拜耳制药股份公司 | 2018-04-20 | — | — | CN | disclosed |
| US-20050065213-A1 | Combretastatin a-4 derivatives having antineoplastic activity | LAWRENCE NICHOLAS JAMES (GB) | 2005-03-24 | — | — | US | disclosed |
| EP-1444190-A1 | COMBRETASTATIN A-4 DERIVATIVES HAVING ANTINEOPLASTIC ACTIVITY | Cancer Research Technology Limited (GB) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040077-A1 | COMBRETASTATIN A-4 DERIVATIVES HAVING ANTINEOPLASTIC ACTIVITY | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-05-15 | — | — | WO | disclosed |
| US-6229016-B1 | PYRIDOPYRIMIDINE DERIVATIVES AS CHEMICAL INTERMEDIATES; POLYMERIZATION INHIBITION OF TUBULIN | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2001-05-08 | — | — | US | disclosed |
| US-6071930-A | FOR INHIBITION OF MITOSIS OR TUMOR GROWTH | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2000-06-06 | — | — | US | disclosed |
| EP-0971921-A1 | 2-ARYL-NAPHTHYRIDIN-4-ONES AS ANTITUMOR AGENTS | The University of North Carolina at Chapel Hill (US) | 2000-01-19 | — | — | EP | disclosed |
| US-5994367-A | PREVENT CELL MITOSIS; ANTICARCINOGENIC AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1999-11-30 | — | — | US | disclosed |
| WO-1998039332-A1 | 2-ARYL-NAPHTHYRIDIN-4-ONES AS ANTITUMOR AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065213-A1 | Combretastatin a-4 derivatives having antineoplastic activity | AURKA, AURKB, HDAC4 | KCNH2 2559/4885SUCNR1 1721/4885PDE10A 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.